Report period | 2019 | 2020 | 2021 | 2022 | 2023 | Q2 24 |
---|---|---|---|---|---|---|
End date of the reporting period | ||||||
Capitalization, $ | ||||||
Capitalization, $ | ||||||
Enterprise Value | ||||||
Book Value | ||||||
Shareholders Book Value | ||||||
Current liabilities | ||||||
Noncurrent liabilities | ||||||
Total liabilities | ||||||
Debt | ||||||
Cash and cash equivalents | ||||||
Net debt | ||||||
Assets | ||||||
Total ordinary shares | ||||||
Ordinary share price |
Ticker | Name | Type | Nominal value | ISIN | Price |
---|---|---|---|---|---|
VCYT:US | Veracyte, Inc. | Common share | - | US92337F1075 | $32 |
Company name | Veracyte |
---|---|
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Life Sciences Tools & Services / Life Sciences Tools & Services |
Business address | 6000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 (650) 243-6300 |
Mailing address | 6000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 |
Website | www.veracyte.com |
Information disclosure | www.sec.gov |